Irina Mamisoa Ranaivo

Irina Mamisoa Ranaivo

Auto-generated profile, based on publicly available information

Irina Mamisoa Ranaivo

Department of Dermatology, Place Kabary Hospital, Antsiranana, Madagascar

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in BioMed Research International
Verified
Journal Article
Open access
PDF file
FSFandresena Arilala Sendrasoa
Fandresena Arilala Sendrasoa
NRNaina Harinjara Razanakoto
Naina Harinjara Razanakoto
VRVolatantely Ratovonjanahary
Volatantely Ratovonjanahary
OROnivola Raharolahy
Onivola Raharolahy
IRIrina Mamisoa Ranaivo
Irina Mamisoa Ranaivo
FRFahafahantsoa Rapelanoro Rabenja
Fahafahantsoa Rapelanoro Rabenja
Background. Psoriasis is a chronic, inflammatory, and multifactorial dermatosis that impairs quality of life (QoL). Health‐related QoL has become an important element in medical decision‐making along with the effectiveness and the harmlessness of the treatments. Objective. To assess the impact of psoriasis in the QoL of patients with psoriasis by using the DLQI scales. Methods. A cross‐sectional study from January to June 2018 was conducted in the Department of Dermatology of the University Hospital Joseph Raseta Befelatanana, Antananarivo, Madagascar, including patients more than 18 years old with mild to severe psoriasis. The severity of psoriasis was assessed using the “Psoriasis Area and Severity Index (PASI)”. QoL of patients with psoriasis was evaluated by using the DLQI scales. Results. 80 patients were included, their mean age was 36.5 years, and the male to female was 1.5 : 1. The mean DLQI score was 13.8. Symptoms, feelings, and psychic were the most altered dimensions. QoL was impaired in young patients, single, having medium level education. Even though patients with disease duration more than 5 years had higher DLQI score than other patients, the difference was not statistically significant (p = 0.36). Furthermore, the clinical presentation of psoriasis did not influence the patient’s QoL (p = 0.73). Patients with nail involvement had QoL impaired but the difference with another localization was not statistically significant (p = 0.2). The quality of life was influenced by body area involved. The higher the body surface area involved, the more QoL is impaired (p = 0.002). Furthermore, the higher the PASI, the more QoL is altered (p = 0.002). Conclusion. Psoriasis has a negative impact in the quality of life in Malagasy patients with psoriasis, especially in younger and single patients. Worse quality of life is correlated to severity of psoriasis.

1 September 2021 in Clinical, Cosmetic and Investigational Dermatology
Verified
Journal Article
Open access
PDF file
FSFandresena Arilala Sendrasoa
Fandresena Arilala Sendrasoa
IRIrina Mamisoa Ranaivo
Irina Mamisoa Ranaivo
ARArifetraniaina Julia Raherivelo
Arifetraniaina Julia Raherivelo
FRFahafahantsoa Rapelanoro Rabenja
Fahafahantsoa Rapelanoro Rabenja
LRLala Soavina Ramarozatovo
Lala Soavina Ramarozatovo
Background: Long-term oral corticosteroids have an important role in dermatological care in Madagascar. However, significant adverse effects have been associated with continuous exposure to oral corticosteroids. Objective: We aim to assess the adverse effects of long-term corticosteroid therapy in patients seen in the Department of Dermatology at the University Hospital Joseph Raseta Befelatanana Antananarivo (UH/JRB), Madagascar, and to identify the risk factors associated with these adverse effects. Methods: A cross-sectional study was conducted during 4 months to assess the adverse effects of long-term corticosteroid therapy in patients seen in the Department of Dermatology. Patients treated with oral corticosteroids for more than 3 months were included in our study. Results: The prevalence of long-term use of oral corticosteroids in the Department of Dermatology of UH/JRB was 34.28%. A total of 51 patients were included and adverse effects occurred in 64.70% of this population. Repetitive infections and cutaneous adverse reactions were the most frequent adverse effects, in 23.52% and 11.76% of cases, respectively. There were no correlations between age, gender, type of disease treated, the molecule used or daily dose and the risk of adverse effects. Patients who received a corticosteroid dose of more than 40 mg daily (longer than 3 months) or a high cumulative dose of corticosteroids had a high risk of adverse effects. Conclusion: Repetitive infections and cutaneous adverse reactions are the most frequent adverse effects of long-term oral corticosteroid use. Prescribing the lowest effective dose may reduce the risk of these adverse effects. Furthermore, prevention of the adverse effects of corticosteroids through diet, calcium and vitamin D supplementation is strongly recommended during long-term oral corticosteroid therapy.

31 May 2019 in International Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
FSFandresena Arilala Sendrasoa
Fandresena Arilala Sendrasoa
IRIrina M. Ranaivo
Irina M. Ranaivo
MSMoril Sata
Moril Sata
MAMalalaniaina Andrianarison
Malalaniaina Andrianarison
OROnivola Raharolahy
Onivola Raharolahy
FRFahafahantsoa Rapelanoro Rabenja
Fahafahantsoa Rapelanoro Rabenja

1 April 2024 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
MRMendrika Fifaliana Rakotoarisaona
Mendrika Fifaliana Rakotoarisaona
TRTsiory Iarintsoa Razafimaharo
Tsiory Iarintsoa Razafimaharo
FSFandresena Arilala Sendrasoa
Fandresena Arilala Sendrasoa
MAMalalaniaina Andrianarison
Malalaniaina Andrianarison
NRNaina Harinjara Razanakoto
Naina Harinjara Razanakoto
FRFahafahantsoa Rapelanoro Rabenja
Fahafahantsoa Rapelanoro Rabenja
Background: Leprosy and tuberculosis are two of the oldest and most common mycobacterial infections, caused by Mycobacterium leprae and Mycobacteium lepramatosis for leprosy and Mycobacterium tuberculosis for tuberculosis. Dual infections have been known since ancient times; however, cases remain rarely reported in the literature, even in countries where both diseases are endemic, such as Madagascar. Purpose: We report a case series of simultaneous occurrence of leprosy and tuberculosis. Patients and Methods: In this retrospective study, we reviewed the medical records of patients with leprosy registered at the Department of Dermatology, University Hospital Befelatanana, Antananarivo, Madagascar, between January 2012 and June 2021. Patients with leprosy and diagnosed as coinfected by tuberculosis were included in the study. Results: Of the 120 leprosy cases observed during the study period, coinfection with leprosy and tuberculosis was found in five patients. The mean age was 43.4 (SD 13.2) ranging, 21– 59 years. Male gender was predominant (4/5). Four patients presented with lepromatous leprosy, and one with borderline lepromatous leprosy. Three patients experienced leprosy reaction. Four cases of pulmonary tuberculosis and one case of multifocal tuberculosis were observed. The diagnosis of leprosy preceded tuberculosis in four cases, and a coinfection diagnosis was made simultaneously in one case. The average time to develop tuberculosis was 38.8 (SD 10.2) months. HIV infection, malnutrition, alcohol consumption, and long-term corticosteroid therapy were the immunosuppressive factors reported in our patients. Three patients received concomitant multidrug therapy for leprosy and tuberculosis. Conclusion: Dermatologists should be aware of the importance of screening patients affected by leprosy for latent or active tuberculosis to prevent morbidity and mortality due to coinfection and to reduce the risk of acquired resistance to rifampicin, which is the greatest risk of this association.

1 January 2021 in Dermatology Research and Practice
Verified
Journal Article
Open access
PDF file
IRIrina Mamisoa Ranaivo
Irina Mamisoa Ranaivo
FSFandresena Arilala Sendrasoa
Fandresena Arilala Sendrasoa
MAMalalaniaina Andrianarison
Malalaniaina Andrianarison
MSMoril Sata
Moril Sata
OROnivola Raharolahy
Onivola Raharolahy
FRFahafahantsoa Rapelanoro Rabenja
Fahafahantsoa Rapelanoro Rabenja
Introduction. The child’s skin diseases are common and very diverse. Many studies concerning pediatric dermatoses have been carried out in Africa and the rest of the world. Few epidemioclinical data reflect these skin diseases in children, especially in the east coast of Madagascar. We aim to describe the pattern skin diseases among children seen at the University Hospital Center Morafeno, Toamasina, Madagascar. Patients and Methods. A retrospective study over a 3‐year period from January 2017 to December 2019 was conducted in children seen in the Dermatology Department of University Hospital Center Morafeno, Toamasina, with skin diseases. Results. During the study period, 347 children out of the 1584 new patients were retained with a sex ratio of 0.86. The mean age was 6.4 years old. The main diseases identified were skin infectious diseases (43, 23%), allergic dermatoses (24.21%), and autonomous dermatosis (15.56%). Conclusion. Our study revealed the importance of infectious and allergic dermatoses in Toamasina. It is necessary to carry out simple preventive actions such as hygiene.

1 March 2023 in International Medical Case Reports Journal
Verified
Journal Article
Open access
PDF file
MRMendrika Fifaliana Rakotoarisaona
Mendrika Fifaliana Rakotoarisaona
TRTsiory Irintsoa Razafimaharo
Tsiory Irintsoa Razafimaharo
NRNaina Harinjara Razanakoto
Naina Harinjara Razanakoto
FSFandresena Arilala Sendrasoa
Fandresena Arilala Sendrasoa
ADAnne Ducournau
Anne Ducournau
FRFahafahantsoa Rapelanoro Rabenja
Fahafahantsoa Rapelanoro Rabenja
Introduction: Idiopathic granulomatous mastitis (IGM) is a rare chronic inflammatory disease. Neoplastic and infectious etiologies must be ruled out. IGM is a diagnostic challenge for countries with high tuberculosis endemicity like Madagascar since it may clinically and radiologically mimic breast tuberculosis. We report a case of IGM associated with erythema nodosum in a Malagasy. Case Report: A 29-year-old primiparous woman came to a dermatological consultation for typical erythema nodosum lesions that appeared one month after a breast swelling. She had no particular medical history. Examination revealed typical erythema nodosum lesions on the legs, voluminous tender mass in the right breast. Bacteriological samples and tuberculosis test were negative. Imaging showed mastitis on the right breast with no evidence of malignancy. Histology revealed a non-caseating granulomas on the lobule of the right breast. As part of an etiological work-up, COVID-19 serology was performed with a positive IgG antibody. The diagnosis of IGM associated with erythema nodosum was evocated. The evolution was favorable under systemic corticosteroid therapy. Discussion: The cause of this uncommon lesion remains obscure. The extramammary localizations such as erythema nodosum and arthralgia suggest an autoimmune origin. This pathogenesis is also reinforced by a good response to systemic immunosuppression. In our patient, the etiological assessment of the mastitis revealed a chronic infection with SARS-CoV-2. Histopathology is the gold standard for the IGM diagnosis which demonstrates a lobulocentric granulomas without caseous necrosis. Oral corticosteroid therapy is the initial choice of treatment. Conclusion: Now, with several cases of concomitant IGM and EN reported, dermatologists should be aware that erythema nodosum can be one of the presenting signs of IGM, since the two conditions appear to be associated. The particularity of our case lies in the incidental discovery of SARS-CoV-2 infection. Is a chronic granulomatous disease associated with SARS-CoV-2 infection, a coincidence?